BridgeBio Oncology Therapeutics Inc.

Healthcare

NASDAQ:BBOT · NASDAQ Global Market

Market Cap $593.59M Beta 0.29 P/E (TTM) -1.6

$7.75 +3.89%

+$0.29 today

52W Low $7.00High $14.87

Vol 0.23M · Avg 0.35M

EPS (TTM)-$4.95

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-32.6%

avg 20391.6%

ROIC

-35.2%

avg -198566.7%

ROA

-29.9%

avg -3907.2%

Analysis

ROA is currently the strongest return metric at -29.9% versus its period average of -3907.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management

Name	Title	Compensation	Tenure	Age	Shares Owned	Ownership %
Yong Ben	Chief Medical & Development Officer	$770,955.00	—	52	$45,623.00	0.06%
Pedro J. Beltran	Chief Executive Officer and Director	$767,662.00	—	55	$1.10M	1.38%
Eli Wallace	Chief Executive Officer and Director	$767,662.00	—	58	$1.11M	1.39%
Frank McCormick	Co-Founder, Non-Executive Director & Chair of the Advisory Board	$65,000.00	—	76	$91,076.00	0.11%
Neil Kumar	Executive Chairman	$20,000.00	—	47	$0.00	<0.01%
Idan Elmelech	Chief Operating Officer	—	—	33	$758,222.00	0.95%
Aaron Chan	Vice President of Legal	—	—	—	—	—
Bin Wang	Senior Vice President of Drug Discovery	—	—	—	—	—
Rui Xu	Senior Vice President of Drug Discovery	—	—	—	—	—
Daniel Watson	Senior Vice President of Chemistry, Manufacturing & Controls	—	—	—	—	—
Marc Cobo	VP of Finance & Controller	—	—	45	$0.00	<0.01%
Angela Peters	Senior Vice President of People	—	—	—	—	—
Howard Y. Chang	Vice President of Operations	—	—	—	—	—
Uneek Mehra	Chief Financial Officer	—	—	53	$22,806.00	0.03%